Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Gilead Sciences, Inc.
Via Business Wire
5 Reasons Gilead Sciences is a Better Buy Than You Think
Gilead Sciences is a value and high-yielding stock on the brink of a stock rebound that could add double-digits to investors portfolios this year an next. 
Via MarketBeat
Exposures COVID-19
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Inc. (NASDAQ: GILD) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Exposures COVID-19
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
From Gilead Sciences, Inc.
Via Business Wire
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains. 
Via MarketBeat
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food... 
Via FinancialNewsMedia
Exposures Product Safety
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead Prices $2 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
Hypertrophic Cardiomyopathy Therapeutics Market Projected to Show Strong Growth : Novartis, Gilead Sciences, ADVANZ PHARMA
Stay up-to-date with Hypertrophic Cardiomyopathy Therapeutics Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Gilead Sciences Announces Second Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
From Gilead Sciences, Inc.
Via Business Wire
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
From Gilead Sciences, Inc.
Via Business Wire
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
From Gilead Sciences, Inc.
Via Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
From The Center for Disease Analysis Foundation
Via Business Wire
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.